Cue Health debuts Cue Clinic™ dashboard to
give healthcare providers more choice and control over patient care
as part of BioReference's product offering
SAN
DIEGO and ELMWOOD PARK,
N.J., April 5, 2022 /PRNewswire/ -- Cue Health
Inc. ("Cue") (Nasdaq: HLTH), the healthcare
technology company behind one of the country's most accurate
COVID-19 tests and BioReference Laboratories, Inc.,
an OPKO Health company ("BioReference"),
today announced that Cue is now an available point-of-care solution
for BioReference's clinical customers, including for
healthcare providers and point-of-care clinics in the
U.S.
Cue's innovative Cue Clinic™ provider dashboard will be the
keystone product offered through BioReference. Cue Clinic will
provide healthcare providers with a full suite of integrated
digital patient care services, including test results from the Cue
Health Monitoring System, virtual care capabilities, scheduling,
e-prescriptions, reporting, and more. Cue Clinic will help
healthcare providers access and utilize digital health capabilities
with integrated diagnostics to modernize their practice, manage
population health, and access timely health analytics to enable
healthcare providers to make more informed care decisions that best
serve their patients' needs.
BioReference will now offer healthcare providers a full-service,
turnkey onboarding process, including CLIA application assistance,
setup, training, and implementation of Cue Clinic as well as the
Cue Health Monitoring System (Reader) as part of the healthcare
providers' own in-house laboratories. The Cue experience starts
with the Cue Reader, a reusable and compact device that processes
each test and delivers results in 20 minutes via the Cue Health
App. The Cue Reader is currently compatible with Cue's COVID-19
Test and other tests that are in development.
"Approximately seventy percent of clinical decisions at the
point of care are made utilizing diagnostic data, but the current
system is inconvenient, inefficient, expensive, and disconnected,"
said Ayub Khattak, CEO and
co-founder of Cue Health. "Together with BioReference, Cue can
empower healthcare providers with the tools and insights they need
to make better-informed care decisions together with their
patients, today and into the future."
By providing actionable information in real-time and at the
point-of-care, Cue empowers healthcare providers to help
individuals proactively monitor and manage their health. Cue's
planned future care offerings – all of which are intended to be
compatible with the Cue Reader – include products and services
across the categories of respiratory health (such as for influenza,
RSV, and strep throat), sexual health (such as for chlamydia and
gonorrhea), cardiac and metabolic health (such as for cholesterol
and HbA1c), women's and men's health, and chronic disease
management.
"BioReference and Cue are jointly focused on developing
innovative solutions to empower our customers. This combined effort
will assist us in supporting the market efficiently and
effectively," said Natalie
Cummins, Chief Commercial Officer for BioReference
Laboratories. "BioReference aims to lift barriers to entry that
block healthcare providers from offering diagnostic testing in
their practices and provide fast, reliable test results, enabling
faster healthcare decisions."
Cue is a testing solution in a number of the nation's leading
healthcare institutions, including Johns Hopkins Medicine, Mayo
Clinic, Memorial Hermann, and UPMC Children's Hospital of
Pittsburgh, as well as
distributors such as Cardinal Health.
BioReference has performed over 1.5 million point-of-care tests
for customers, and BioReference's new offering is focused on
bringing point-of-care solutions to providers' in-house
laboratories. The offering provides state-of-the-art point-of-care
solutions, supporting clients from set-up and training to operation
and troubleshooting for their point-of-care laboratories.
About BioReference Laboratories,
Inc.
BioReference Laboratories, Inc., is one of the largest
full-service specialty laboratories in the United States that gives healthcare
providers and patients the power to make confident healthcare
decisions. With a focus on genetics, oncology, urology and women's
health, BioReference offers comprehensive test solutions and
unparalleled expertise based on a 40-year legacy of proven science.
The company is in-network with the largest health plans in
the United States, serves
approximately 19 million patients annually, operates a network of
11 laboratory locations, and is backed by a highly experienced
medical staff, genetic counselors and other professional clinical
and scientific personnel. With a national footprint and niche
market experience, BioReference provides credible and innovative
solutions that meet the needs of employers, governmental agencies,
educational systems, hospitals and health systems, correctional
institutions, sports leagues, travel and leisure industries, and
retail markets. BioReference provides industry-leading custom
solutions for COVID-19, including point-of-care testing and
large-scale screening programs. For more information visit
https://www.bioreference.com/ or on Facebook, Twitter, Instagram
and LinkedIn.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easy for individuals to access health information and
places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
Forward-Looking
Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements". The words, without limitation,
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the "Risk Factors" section
of the Form 10-Q dated November 10,
2021 filed by Cue with the SEC. Any forward-looking
statements contained in this press release are based on the current
expectations of Cue's management team and speak only as of the date
hereof, and Cue specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
These products have not been FDA cleared or approved; but
have been authorized by FDA under an Emergency Use Authorization
(EUA). These products have been authorized only for the detection
of nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of these products is only authorized
for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-and-bioreference-laboratories-bring-point-of-care-solutions-to-the-clinical-setting-301517725.html
SOURCE Cue Health Inc.